Suzanne Callander reports on two recent additions to the Medtech Innovation Briefing documents produced by NICE, both of which focus on alternative solutions as part of cancer treatment.
There were nearly 16,000 bowel cancer deaths in the UK in 2014 which makes it the most common cause of cancer death here, amounting to 10% of all cancer deaths.
Major surgical resection is the main treatment for early stage colon cancer and Cancer Research UK statistics state that more than six-in-ten colorectal cancer patients will receive this as part of their treatment.
The resected tissue is then assessed by a pathologist to grade and stage the cancer. The resected tissue needs to be processed and cut into sections or levels, stained using haematoxylin and eosin and examined under a microscope. In its standards and datasets for reporting cancers, The Royal College of Pathologists recommends that at least 12 regional lymph nodes (LNs) from the resected tissue are investigated, while National Institute for Health and Care Excellence (NICE) guidance on diagnosing and managing colorectal cancer recommends that pathological characteristics of the lesion, imaging results, and previous treatments should be considered when deciding further treatment in locally excised, pathologically confirmed stage I cancer.
Log in or register FREE to read the rest
This story is Premium Content and is only available to registered users. Please log in at the top of the page to view the full text.
If you don't already have an account, please register with us completely free of charge.
